Dr. Yang Jinfu (楊金夫), aged 63, is our co-founder, the chairperson of the Board, an executive Director and chief executive officer of the Group. He has served as a Director and the chairperson of the Board since June 2018. Dr. Yang was appointed as our chief executive officer in December 2025, and was redesignated as an executive Director in January 2026. He also holds directorships across all subsidiaries within our Group. He is mainly responsible for leading the Board and management team, formulating and executing strategy, and overseeing the Group’s daily operations. Early in Dr. Yang’s career, he conducted academic research at Changchun Institute of Applied Chemistry, Chinese Academy of Sciences (中國科學院長春應用化學研究所), University of Graz in Austria, University of Dortmund in Germany (sponsored by the Alexander von Humboldt Foundation), and Southern Illinois University at Carbondale in the United States. In August 2002, he joined Cytokinetics Inc (NASDAQ: CYTK) as a scientist. From May 2006 to December 2009, he served as an associate director of drug metabolism and pharmacokinetics at Proteolix Inc. (a company was then acquired by Onyx Pharmaceuticals Inc. (NASDAQ: ONXX)). From July 2010 to July 2013, Dr. Yang was with Calithera Biosciences Inc, USA as a director of drug metabolism and pharmacokinetics. Dr. Yang then was the chief executive officer and a director at Ningbo Shengjian Biomedical Technology Co., Ltd. (寧波聖健生物醫藥科技有限公司) from July 2013 to June 2016, and the chief executive officer at Tianyin Biopharmaceutical Technology (Hangzhou) Co., Ltd. (天因生物醫藥科技（杭州）有限公司) from July 2016 to June 2019. Dr. Yang obtained a Ph.D. from Changchun Institute of Applied Chemistry, Chinese Academy of Sciences (中國科學院長春應用化學研究所) in the PRC in 1988. Dr. Yang is a recipient of numerous accolades. His key recognitions include being selected as (i) a Distinguished Expert of National Major Talent Project (國家重大人才工程計劃專家), (ii) a Humboldt Research Fellow of the Alexander von Humboldt Foundation, (iii) a High-end Foreign Expert recognized by the State Administration of Foreign Experts Affairs of the PRC (國家外專局高 端外國專家), (iv) a Leading Talent of “3315 Plan” in Ningbo (寧波市“3315”計劃領軍人才), and (v) a High-end Foreign Expert of the Zijinshan Elite Talent Pioneer Program in Nanjing (南京市紫金山英才先鋒計劃高端外國專家). 

Dr. Hao Xiaolin (郝小林), aged 56, is our co-founder, executive Director and chief scientific officer. He has served as a Director since June 2018. He was our chief executive officer from June 2018 to December 2025. Dr. Hao was appointed as our chief scientific officer in December 2025, and was redesignated as our executive Director in January 2026. He also serves as a director of Zenshine CA. He is mainly responsible for leading research and development, including the formulation, implementation and execution of the Group’s drug discovery and development strategies.

Dr. Hao commenced his career in the biopharmaceutical industry in September 1999 when he joined Tularik Inc as a scientist. In August 2004, he assumed the role of principal scientist at Amgen Inc. (NASDAQ: AMGN) through October 2014. Dr. Hao founded AIM Biosciences Inc. in February 2015, where he acted as the chief executive officer until 2020. Dr. Hao obtained a bachelor’s degree in chemistry from Peking University (北京大學) in the PRC in July 1991, a master’s degree in bio-organic chemistry from Peking University in the PRC in July 1994, and a Ph.D. in organic chemistry from University of Illinois Chicago in the United States in 1999. Dr. Hao served as the president of the Chinese American Biopharmaceutical Society from 2014 to 2015 and has sat on its board since 2015. Dr. Hao is also a recipient of numerous accolades. His key recognitions include being selected as (i) a Distinguished Expert of National Major Talent Project (國 家重大人才工程計劃專家), and (ii) a Talent of the Zijinshan Elite Talent Pioneer Program in Nanjing (南京市紫金山英才計劃高峰項目入選人才).

Mr. Xu Ming (許明), aged 52, has been the chief operating officer and Board secretary of our Group since November 2025. He is mainly responsible for managing daily business operations, executing corporate strategies, and optimizing organizational efficiency. Mr. Xu commenced his career in January 1996 at Merck Sharp & Dohme (a subsidiary of Merck & Co., Inc. (NYSE: MRK)). In August 1998, he joined Bayer HealthCare (a healthcare division of Bayer AG (FWB: BAYN)), where he served as national commercial manager and later as national commercial and sales administration manager until March 2003. He then employed by Dr. Reddy’s Laboratories (NYSE: RDY), serving as a national commercial manager from September 2003 until his promotion to financial manager in April 2006. Afterwards, Mr. Xu was a business development vice president at China NT Pharma Group Company Limited (SEHK: 1011) until May 2014. In September 2015, Mr. Xu joined Ambrx Biopharma, Inc. (NASDAQ: AMAM), where he acted as general manager and board secretary until November 2018, and subsequently as China strategic vice president until November 2019. During this period, he also served as a senior healthcare advisor at HOPU Investments (厚樸投資) from October 2018 to July 2021 and as an executive director at CMH Health Fund from December 2019 to April 2021. Prior to joining our Group, Mr. Xu was the co-founder and chief operating officer at Ablaze Pharmaceuticals from May 2021 to August 2024. Mr. Xu obtained a bachelor’s degree in pharmacy from Fudan University (復旦大學) in the PRC in July 1995 and an EMBA from Fudan University (復旦大學) in the PRC in July 2007.

Dr. Sun Min (孫敏), aged 44, has been the senior vice president (CMC) of our Group since February 2024. He is mainly responsible for overseeing chemistry, manufacturing, and controls (CMC) functions, including process development, production, and quality assurance. Dr. Sun commenced his career in biopharmaceutical industry in June 2010 when he joined Jiangsu Aosaikang Pharmaceutical Co., Ltd. (江蘇奧賽康藥業有限公司), with his last position being a deputy general manager and deputy director of the drug research institute. He joined our Group in September 2021 as vice president (CMC) and was promoted to senior vice president (CMC) in February 2024. Dr. Sun obtained a Ph.D. in pharmaceutical engineering (製藥工程) from Southeast University (東南大學) in the PRC in December 2009.

Dr. Sun is a recipient of numerous accolades. His key recognitions include being selected as (i) an Innovation and Entrepreneurship Doctor in Jiangsu (江蘇省雙創博士), (ii) a High-level Talent of Six Talent Peaks in Jiangsu (江蘇省六大人才高峰高層次人才); (iii) a 333 High-level Talent in Jiangsu (江蘇省 333高層次人才); and (iv) a Top-notch Young and Middle-aged Talent in Nanjing (南京市中青年拔尖人才).

Mr. Gui Yaokui (桂耀奎), aged 47, has been the senior vice president (Commercialization) of our Group since June 2023. He is mainly responsible for driving business development, market access strategies, commercialization, and brand management. Mr. Gui commenced his career in January 2004 as a pharmaceutical representative at GlaxoSmithKline (China) Investment Co., Ltd. (葛蘭素史克（中國）投資有限公司) (a subsidiary of GSK plc (LSE: GSK)), where he rose to a senior regional manager before his departure in March 2015. From March 2015 to April 2018, he successively assumed the role of operation and strategy director and marketing director at Hisun-Pfizer Pharmaceutical Co., Ltd. (海正輝瑞製藥有限公司). Mr. Gui joined Sunshine Lake Pharma Co., Ltd. (廣東東陽光藥業股份有限公司) (SEHK: 6887) in February 2018 and remained there until February 2021, with his last position being deputy general manager. Prior to joining our Group, he was the deputy general manager at Sansure Biotech Inc. (聖湘 生物科技股份有限公司) (SSE: 688289) from March 2021 to January 2022. Mr. Gui obtained a bachelor’s degree in Chinese medicine from Anhui University of Chinese Medicine (安徽中醫藥大學) in the PRC in July 2002.

Ms. Wang Xiaoyan (汪曉燕), aged 48, has been the financial executive director of our Group since May 2023. She is mainly responsible for directing financial and accounting management. Earlier in Ms. Wang’s career, from June 2005 to April 2010, she was employed by Bayer CropScience (China) Co., Ltd. (拜耳作物科學（中國）有限公司) (a subsidiary of Bayer AG (FWB: BAYN)) as a financial accountant. Ms. Wang then was a finance controller at Hangzhou Sanofi Minsheng Consumer Healthcare Co., Ltd. (杭州賽諾菲民生健康藥業有限公司) (a subsidiary of Sanofi (Euronext: SAN; NASDAQ: SNY)) until August 2016. Ms. Wang then was a senior manager at Innovent Biologics (Suzhou) Co., Ltd. (信達生物製藥（蘇州）有限公司) (a subsidiary of Innovent Biologics, Inc. (SEHK: 1801)) until January 2017. She served as a financial director at Ascletis Pharma Inc. (歌禮製藥有限公司) (SEHK: 1672) from February 2017 to April 2021. Prior to joining our Group, she was the senior financial director at Exegenesis Bio Inc (杭州嘉因生物科技有 限公司) from May 2021 to May 2023. Ms. Wang obtained a bachelor’s degree in accounting from Anhui Finance and Economics University (安徽財經大學) in the PRC in June 2002 and a master’s degree in accounting from Shanghai National Accounting Institute (上海國家會計學院) in the PRC in October 2012. Ms. Wang is a High-level Accounting Talent in Hangzhou, and has been a certified management accountant since December 2015.